Stephen J. Haggarty,Daniel Fass,Jennifer Pan,Josh Ketterman,Edward Holson,Tracey Lynn Petryshen,Michael C. Lewis
申请号：
US12660591
公开号：
US09265764B2
申请日:
2010.02.27
申请国别(地区):
US
年份:
2016
代理人:
摘要：
Aspects of this invention are related, at least in part, to the use of chemical compounds able to inhibit GSK-3 and/or to stabilize β-catenin and formulations thereof. Some aspects of this invention relate to compositions comprising such compounds. Some aspects of the invention provide methods of using such compounds and/or compositions in the treatment of subjects having a neurological disease and/or psychiatric disorder. Some aspects of this invention provide methods of using ruboxistaurin, enzastaurin, sunitinib, midostaurin, lestaurtinib, 7-hydroxystaurosporine, and/or Chir99021 in the treatment of subjects having a neurological disease and/or psychiatric disorder. In some embodiments, compounds are administered in combination with Lithium.
